3 Vaccine Stocks With Big Opportunities Outside of COVID-19 The Motley Fool

covid vaccine stocks

Johnson & Johnson is also in a position to boost its growth through acquisitions. The company ended the second quarter with $25.8 billion in cash, cash equivalents, and marketable securities. It’s shown in the past a willingness to use its cash to make strategic deals. There are other advantages of regression analysis reasons Wall Street likes AstraZeneca’s prospects, though. Several of the company’s cancer drugs continue to enjoy strong momentum. The vaccine will be marketed under the brand name Comirnaty, and the FDA hopes the approval will nudge unvaccinated people to get vaccinated.

These developments and learnings from the Covid-19 pandemic should bode well for these companies in the long run. The company has partnerships with several other biopharma firms for collaboration on research and development. The vaccine is in the final stage of clinical development and the firm has entered into agreements with other pharma giants for the production of more than 300 million doses of the vaccine by the end of 2021. At the end of the fourth quarter of 2020, 9 hedge funds in the database of Insider Monkey held stakes worth $23 million in the firm, the same as in the preceding quarter worth $54 million. The data released by the firm indicated the Novavax vaccine was effective against new strains of the virus too, putting it ahead of other competitors in this regard. Last week, the British government announced that 10 million doses of the Novavax vaccine would be produced and packaged in England.

Looking at Novavax’s prospects

Moderna landed at No. 211 on this year’s Fortune 500 list with $19.3 billion in revenue. A competitor in the COVID vaccine space, Pfizer, landed at No. 38 on the list, with $100.3 billion in revenue. But CFO Jamey Mock has another narrative he wants people to know about—and the story goes way beyond shots. The company, with its partner the Serum Institute of India, has already filed for EUAs in India, Indonesia, and the Philippines for COVID vaccine candidate NVX-CoV2373. Novavax expects to file for EUA with the United Kingdom in the third quarter of 2021. It plans to file for EUA with regulators in the European Union, Canada, Australia, and New Zealand soon afterward, with a U.S. filing in the fourth quarter.

covid vaccine stocks

Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax (NVAX.O) have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Right now, Pfizer stock is trapped below its 50-day moving average with an IBD Digital Relative Strength Rating of 23. This puts shares in the bottom quarter of all stocks when it comes to 12-month performance. COVID-related products, including therapeutics, brought $21.5B in sales for U.S.-based Pfizer (PFE), Moderna (MRNA), and Novavax (NVAX) in Q2 2022, according to a Seeking Alpha analysis based on the companies’ SEC filings. With the pandemic in the rearview mirror, Wall Street has mixed views on the prospects of COVID-19 vaccine makers, as the group, once the favorite among investors, is grappling with a steep decline in sales amid falling infections.

Exclusive: Rotavirus childhood vaccine shortage hits four African countries

Moreover, the Covid-19 vaccine market is also likely to get increasingly competitive as time goes on, as new players enter the fray and existing players scale up capacity. Pfizer, for instance, says that it could scale up capacity from two billion doses this year to as much as three billion in 2022. Considering this, we think that investors will need to evaluate these companies based on the potential of their future pipelines, rather than just focusing on their Covid vaccines. To determine the best vaccine stocks to buy now, we screened for vaccine companies that had innovative products, solid pipelines, and industry-leading positions.

Novavax (NVAX) Stock Increases 9% in a Month: Here’s Why – Nasdaq

Novavax (NVAX) Stock Increases 9% in a Month: Here’s Why.

Posted: Tue, 05 Sep 2023 16:10:00 GMT [source]

Democratic Rep. Don Beyer of Virginia reported buying up to $15,000 worth of Regeneron Pharmaceuticals stock in May 2020 through a jointly held account. He sold up to $30,000 worth of the stock between July and August 2020 through a jointly held account. Dozens of Republican and Democratic lawmakers on Capitol Hill have invested in companies that have a direct stake in the nation’s response to the COVID-19 pandemic, according to an Insider analysis of federal financial records.

Johnson & Johnson (JNJ) exited the competition this year with a request to revoke the emergency use authorization granted for its vaccine. Even at the start of the pandemic, I wouldn’t buy a company just for its vaccine https://1investing.in/ if the rest of the portfolio looked weak. It’s best to favor long-term investments, or those that could deliver over a period of years — and if they also offer you some rapid gains in the meantime, that’s a bonus.

Covid Vaccine Rally Dashed As Pfizer, Moderna Give Back Gains On Eris’ Advance

“But almost none of them had ever worked on mRNA vaccines. It is a very different vaccine manufacturing platform.” “We’re not waiting until we have finished a turnkey process,” notes Terblanche, “because we are building capacity for future pandemics. So speed is important.” “If you’d asked me 18 months ago,” she says, I would have said to you, ‘It’s not possible.’ So I’m very upbeat.”

A full approval of Moderna’s COVID-19 vaccine is expected in the next few weeks. See our indicative theme on Covid-19 Vaccine stocks for more details on the performance of key U.S.-based companies working on Covid-19 vaccines. Still, it’s now priced at 11 times estimated earnings, down from 147 times in July 2020. The recent selloff finally brought the stock back in line with analysts’ 12-month projections for the first time in more than four months. Nineteen months into the pandemic, a successful rollout of a Covid-19 pill could quicken and broaden the world’s recovery, opening up a plethora of investment opportunities in stock markets. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

What to know about investing in COVID-19 vaccine stocks

Children 6 months through 5 years of age who are getting their vaccines for the first time should complete their primary series with two doses of an updated Moderna shot or three doses of a new Pfizer jab, according to the CDC. If children previously received prior vaccines, the CDC has different recommendations for how many updated doses to get. Public health officials and health experts hope the arrival of new vaccines will help the U.S. avoid another severe Covid wave and “tripledemic” of Covid, the flu and respiratory syncytial virus, which inundated hospitals last winter. The Biden administration said last month that it will encourage eligible Americans to receive an updated Covid vaccine alongside an annual flu shot and an RSV jab approved for older adults or mothers.

COVID Vaccine Sales Are Declining. But Here’s How They’re Still … – Nasdaq

COVID Vaccine Sales Are Declining. But Here’s How They’re Still ….

Posted: Fri, 08 Sep 2023 10:00:00 GMT [source]

This gap is due to several factors, including a lower overall efficacy for J&J’s vaccine and some rare blood-clotting issues. Under a law passed early in the pandemic, private insurers have been required to cover COVID-19 vaccines “immediately upon the vaccine becoming authorized or approved” by the FDA. This is different than other vaccines, which insurers typically have several months to implement coverage for. Newer descendant strains have since emerged, though vaccine makers have announced early findings suggesting their shots will also work for the latest strains on the rise. The FDA said it greenlighted at least one dose of the updated vaccines for Americans as young as 6 months old. But the info package only covers how to make small quantities of the vaccine.

Archie Smith, the husband of Democratic Sen. Tina Smith of Minnesota, held up to $250,000 worth of 3M shares, according to her annual disclosure. Vivien Scott, the wife of Rep. Austin Scott, a Republican of Georgia, traded up to $50,000 worth of Johnson & Johnson stock on two occasions this year. Austin Scott has bashed President Joe Biden’s workplace vaccine mandates but stressed that he supports vaccines, particularly given that he had COVID-19 in 2020 and spent several days in the hospital on oxygen. After dropping steadily through the autumn, it began rising again in late November.

covid vaccine stocks

Struggling with its COVID-19 vaccine isn’t a critical blow to AstraZeneca. The drug company’s lineup includes several products with strong sales growth, especially its cancer drugs Imfinzi and Lynparza. Its drug pipeline is also well-developed and features a large number of late-stage candidates. Is it too late to invest in the stocks of leading COVID-19 vaccine makers? Sure, vaccines are now widely available in the U.S., Canada, and Europe.

Qualified blind trusts can be expensive and time-consuming to establish, but congressional guidance suggests they provide the “most comprehensive approach” to avoiding “potential conflicts of interest or the appearance of such conflicts.” Rep. John Yarmuth, a Democrat of Kentucky who chairs the House Budget Committee, sold up to $15,000 worth of stock in 3M, which creates and distributes personal protective equipment such as N95 masks, at the end of March 2020. Martha Brooks, the congressman’s wife, told Insider that she handled all the family’s stock investments and used an investment broker to conduct these transactions. “Congressman Scott and his wife own stocks like millions of American families do, and they follow all laws on trading,” Scott’s spokeswoman, Rachel Ledbetter, told Insider. —Salesforce CEO Marc Benioff said in a conversation with CNBC’s Jim Cramer on Tuesday that the company’s messaging program Slack will have its own A.I.

  • Novavax wrapped up the final analysis for its seasonal flu vaccine’s pivotal trial in September, and the study’s results were subsequently published in The Lancet Infectious Diseases.
  • So if a patient has upcoming travel or a large gathering to attend in mid-October, they could plan to get the new shot at the beginning of that month.
  • Children 6 months through 5 years of age who are getting their vaccines for the first time should complete their primary series with two doses of an updated Moderna shot or three doses of a new Pfizer jab, according to the CDC.
  • People who are moderately or severely immunocompromised should get one or more doses of a new shot, depending on their vaccination history.
  • The program will begin as soon as vaccines have reached participating providers, which include CVS and Walgreens, according to Twentyman.

In rare cases, there were concerns about potential blood clotting linked to its vaccine. AstraZeneca also struggled to meet supply targets, resulting in the E.U. On Monday, Pfizer put some of that cash to work and announced the acquisition of Trillium Therapeutics, a early-stage clinical drug company working on blood cancer treatments. The acquisition cost $2.3 billion and Pfizer expects it to add to its growth prospects in 2026 and beyond. Another tiny company, Synairgen Plc of the U.K., was one of the last year’s investor favorites, soaring 2,520% on optimism for its inhaled treatment for Covid-19.

Leave a Comment

Your email address will not be published. Required fields are marked *